The Myelofibrosis market in the 7MM is set to grow significantly, found to be USD 2.6 billion in 2025. Myelofibrosis market is expected to grow at a CAGR of 9%. The United States dominates the Myelofibrosis market, holding nearly USD 1.7 billion of the total value in 2024. JAK inhibitors remain the backbone of treatment, with JAKAFI/JAKAVI leading the market at around USD 1.5 billion in 2024 due to its proven efficacy in symptom relief, spleen reduction, and quality-of-life improvement.
DelveInsight’s report, “Myelofibrosis Market Insights, Epidemiology, and Market Forecast 2034,” provides a comprehensive analysis of the disorder, including detailed historical and projected epidemiology, along with market size and share across the seven major markets (7MM)—the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The report examines emerging therapies, current treatment approaches, individual drug market performance, and market trends from 2020 through 2034. It further assesses treatment algorithms, key market drivers and challenges, and existing unmet needs to identify growth prospects and evaluate the market’s overall potential.
According to DelveInsight, the Myelofibrosis market is expected to undergo significant expansion in the coming years, driven by the increasing patient population and the introduction of novel therapeutic options.
Discover How the Myelofibrosis Market Will Grow by 2034 @ Myelofibrosis Market Forecast
Myelofibrosis Market Report Key Facts
Explore Emerging Myelofibrosis Treatments: Access Detailed Clinical Trial Analysis, JAK Inhibitor Trends, and Novel Mechanisms Targeting Cytopenia and Anemia @ Myelofibrosis Treatment Market
Myelofibrosis Overview
Myelofibrosis is a rare, chronic myeloproliferative neoplasm characterized by the abnormal proliferation of bone marrow stem cells, leading to progressive fibrosis, impaired hematopoiesis, and extramedullary blood formation. The disease arises from acquired mutations—most commonly JAK2, CALR, or MPL—that dysregulate the JAK-STAT signaling pathway, resulting in symptoms such as severe anemia, splenomegaly, fatigue, night sweats, bone pain, and weight loss. As bone marrow scarring worsens, patients often develop cytopenias and an increased risk of acute myeloid leukemia transformation. Diagnosis is based on blood tests, bone marrow biopsy, and molecular profiling. Treatment focuses on symptom management and disease modification through JAK inhibitors (e.g., ruxolitinib, fedratinib), anemia-directed therapies, and splenomegaly control. Allogeneic stem cell transplantation remains the only curative option but is limited to select candidates due to its risks. Ongoing research into targeted and combination therapies aims to improve survival, quality of life, and long-term outcomes for affected individuals.
Myelofibrosis Market Outlook
The myelofibrosis market is expanding rapidly, driven by unmet needs beyond current JAK inhibitor therapies. In 2024, the total market size across the 7MM reached approximately USD 2.2 billion, with the United States contributing nearly USD 1.7 billion—over 75% of total revenue. Within Europe, Germany led the EU4+UK market, while the UK represented the smallest share.
JAK inhibitors remain the backbone of treatment, with JAKAFI/JAKAVI (ruxolitinib) expected to retain market leadership through 2034. Despite newer approvals—INREBIC (2019), VONJO (2022), and OJJAARA (2023)—none have displaced ruxolitinib as the dominant revenue driver.
Going forward, pipeline therapies such as Navtemadlin, Selinexor, Imetelstat, Luspatercept, and Pelabresib are expected to reshape the competitive landscape, especially as combination or post-JAK options.
However, curative treatments remain scarce, with allogeneic transplantation limited to select patients, underscoring continued opportunity for disease-modifying or safer long-term therapies.
Get Key Insights into the Evolving Myelofibrosis Epidemiology Trends @ Myelofibrosis Patient Pool Forecasting
Myelofibrosis Epidemiology
In 2024, the total prevalence of myelofibrosis across the 7MM was approximately 55,900 cases, with numbers expected to rise through 2034. Among EU4 and the UK, Germany reported the highest diagnosed prevalence, while the UK had the lowest. In the US, high-risk myelofibrosis represented the largest patient group, with primary myelofibrosis accounting for around 75% of cases. Age distribution showed that patients aged 70 and above formed the largest segment (~12,100 cases). Additionally, JAK2 mutations were present in roughly 60% of US cases.
The Report Covers the Myelofibrosis Epidemiology Segmented as –
Myelofibrosis Competitive Landscape and Therapeutics
The myelofibrosis treatment pipeline is rapidly evolving, with multiple mid- and late-stage therapies poised to reshape the market. Key emerging candidates include XPOVIO (Karyopharm), Elritercept (Takeda/Keros), Navtemadlin (Kartos), Pelabresib (Novartis), INCB057643 (Incyte), and Bomedemstat (Merck), many of which are being tested across different treatment lines and in combination with existing JAK inhibitors.
Notable innovations include Incyte’s BET inhibitor INCB057643, now in Phase II trials with ruxolitinib, and RYTELO (imetelstat), a telomerase inhibitor demonstrating disease-modifying effects in Phase III studies for JAK-inhibitor–refractory patients. Elritercept, an activin inhibitor targeting anemia in hematologic cancers, is advancing through Phase II under a global licensing deal with Takeda.
As these therapies progress toward approval, they are expected to broaden treatment mechanisms beyond JAK inhibition, establish new standards of care, and significantly expand the myelofibrosis market.
Emerging and Marketed Myelofibrosis Therapies Covered in the Report Include
Explore More About Ongoing Pipeline Development Activities in the Myelofibrosis Market @ Myelofibrosis Drugs and Companies
Myelofibrosis Therapeutics Assessment
The treatment goal for most patients with myelofibrosis is to relieve symptoms, reduce an enlarged spleen, improve blood cell counts (i.e., anemia), and reduce the risk of complications. No drug therapy can cure myelofibrosis. The only potential cure for myelofibrosis is allogeneic stem cell transplantation, but this procedure is risky for older patients and those with other health problems. As myelofibrosis primarily affects older adults, stem cell transplantation is not a treatment option for most myelofibrosis patients. For most people with myelofibrosis, treatment remains aimed at controlling disease symptoms and complications, enhancing the quality of life, and extending survival.
Several major pharma and biotech companies are actively engaged in the development of therapies for Myelofibrosis, a serious bone marrow disorder. Among these companies, Incyte Corporation takes a prominent position, with its Myelofibrosis drug candidates progressing to the most advanced stage of clinical development, specifically in Phase III trials.
Myelofibrosis Market Drivers
Myelofibrosis Market Barriers
Leading Companies in the Myelofibrosis Therapeutics Market Include
Notable players in the Myelofibrosis Therapeutics Market Include Incyte Corporation, Keros Therapeutics, Karyopharm Therapeutics, Celgene Corporation, PharmaEssentia, Novartis, SecuraBio, Pharmaxis, Novartis Oncology, AstraZeneca, Cellenkos, Jacobio Pharmaceuticals, Ohmoncology, Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, Menarini Group, Telios Pharma, Novartis Pharmaceuticals, NS Pharma, Celgene/Bristol-Myers Squibb, MorphoSys, Imago BioSciences, and Roche.
Benchmark Your Strategy Against Competitors: Access DelveInsight’s Myelofibrosis Competitive Intelligence on Leading Companies, Emerging Drugs, and Market Shares – Myelofibrosis Therapeutics Market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Myelofibrosis Competitive Intelligence Analysis
4. Myelofibrosis Market Overview at a Glance
5. Myelofibrosis Background and Overview
6. Myelofibrosis Patient Journey
7. Myelofibrosis Epidemiology and Patient Population
8. Myelofibrosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Myelofibrosis Unmet Needs
10. Key Endpoints of Myelofibrosis Treatment
11. Myelofibrosis Marketed Products
12. Myelofibrosis Emerging Therapies
13. Myelofibrosis Seven Major Market Analysis
14. Attribute Analysis
15. Myelofibrosis Market Outlook (7 major markets)
16. Myelofibrosis Access and Reimbursement Overview
17. KOL Views on the Myelofibrosis Market.
18. Myelofibrosis Market Drivers
19. Myelofibrosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting/conference-coverage-services
